Hôpital Foch
- Address
- lock Available on a paid plan
Digestive System Diseases
The research team at Hôpital Foch is evaluating new post‑surgical strategies for ampullary adenocarcinoma, aiming to increase the proportion of patients who remain cancer‑free two years after operation.
- Adjuvant chemotherapy after surgical resection
- Modified FOLFIRINOX regimen versus standard agents
- Improving two‑year disease‑free survival rates
This work reflects the site’s commitment to advancing treatment options for rare gastrointestinal tumors.
Neoplasms
A pivotal study at Hôpital Foch investigates a novel combination of LY3537982 with pembrolizumab for patients whose KRAS G12C‑mutant non‑small cell lung cancer is advanced, seeking to define the most effective first‑line regimen.
- First‑line targeted therapy for KRAS‑mutated lung cancer
- Combination with immunotherapy to boost response
- Dose‑optimization to balance efficacy and safety
The trial highlights the centre’s focus on precision oncology and collaborative drug development.
Circulatory and Respiratory Physiological Phenomena
Two parallel programs at Hôpital Foch address critical lung and vascular conditions: one examines intravenous thrombolysis in patients with acute ischemic stroke who have recently taken direct oral anticoagulants, while the other compares antifungal strategies—including itraconazole plus nebulised Ambisome®—for chronic pulmonary aspergillosis.
- Evaluating IV thrombolysis safety in anticoagulated stroke patients
- Optimizing antifungal regimens for chronic lung infection
- Measuring clinical and radiological outcomes across both studies
These investigations illustrate the department’s dedication to improving outcomes in both vascular emergencies and persistent respiratory infections.
Miscellaneous Research
Beyond disease‑specific projects, Hôpital Foch conducts a suite of clinical trials that integrate multidisciplinary expertise, rigorous safety oversight, and patient‑focused design across four therapeutic domains.
- Multidisciplinary collaboration among four investigators
- Patient‑centered trial design and enrollment
- Comprehensive safety monitoring across studies
The site’s diverse portfolio underscores its role as a leading hub for innovative clinical research in Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hôpital Foch
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Efficacy of Itraconazole and Nebulised Amphotericin B in Non-Immunocompromised Chronic Pulmonary Aspergillosis Patients | Centre Hospitalier Universitaire De Poitiers | Phase III | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alteplase | 1 | Unknown | 2025-08-04 | 2025-08-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.